Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis
CONCLUSION: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates.PMID:37710179 | PMC:PMC10503112 | DOI:10.1186/s12575-023-00217-y
Source: Biological Procedures Online - September 14, 2023 Category: Molecular Biology Authors: Min Wu Shihao Wu Yuetong Chen Liangchao Sun Jundong Zhou Source Type: research
Fatty acid metabolism-related genes as a novel module biomarker for kidney renal clear cell carcinoma: Bioinformatics modeling with experimental verification
CONCLUSIONS: In this study, a novel risk score model and a module biomarker based on FAM-related genes were screened for KIRC prognosis. More clinical carcinogenic validations will be performed for future translational applications of the findings.PMID:37708719 | PMC:PMC10502355 | DOI:10.1016/j.tranon.2023.101774
Source: Translational Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Zongming Jia Zhenyu Fu Ying Kong Chengyu Wang Bin Zhou Yuxin Lin Yuhua Huang Source Type: research
Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis
CONCLUSION: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates.PMID:37710179 | PMC:PMC10503112 | DOI:10.1186/s12575-023-00217-y
Source: Biological Procedures Online - September 14, 2023 Category: Molecular Biology Authors: Min Wu Shihao Wu Yuetong Chen Liangchao Sun Jundong Zhou Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research
Clin Genet. 2023 Sep 14. doi: 10.1111/cge.14424. Online ahead of print.ABSTRACTCancer, one of the leading causes of death, usually commences and progresses as a result of a series of gene mutations and dysregulation of expression. With the development of clustered regularly interspaced palindromic repeat (CRISPR)/Cas9 gene-editing technology, it is possible to edit and then decode the functions of cancer-related gene mutations, markedly advance the research of biological mechanisms and treatment of cancer. This review summarizes the mechanism and development of CRISPR/Cas9 gene-editing technology in recent years and descri...
Source: Clinical Genetics - September 14, 2023 Category: Genetics & Stem Cells Authors: Li Ning Jiahui Xi Yin Zi Min Chen Qingjian Zou Xiaoqing Zhou Chengcheng Tang Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer
This study suggests an emerging strategy based on a combination of EZH2 inhibitor and immunotherapy based on PD-1 inhibition.PMID:37708707 | DOI:10.1016/j.intimp.2023.110918
Source: International Immunopharmacology - September 14, 2023 Category: Allergy & Immunology Authors: Mengmeng Lv Sheng Guo Xinyu Zhang Yan Zou Qiang Chen Chongyi Zang Shuo Huang Yuhan Hu Yanling Wang Qianqing Wang Jiateng Zhong Source Type: research
Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis
CONCLUSION: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates.PMID:37710179 | PMC:PMC10503112 | DOI:10.1186/s12575-023-00217-y
Source: Biological Procedures Online - September 14, 2023 Category: Molecular Biology Authors: Min Wu Shihao Wu Yuetong Chen Liangchao Sun Jundong Zhou Source Type: research
Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research
Clin Genet. 2023 Sep 14. doi: 10.1111/cge.14424. Online ahead of print.ABSTRACTCancer, one of the leading causes of death, usually commences and progresses as a result of a series of gene mutations and dysregulation of expression. With the development of clustered regularly interspaced palindromic repeat (CRISPR)/Cas9 gene-editing technology, it is possible to edit and then decode the functions of cancer-related gene mutations, markedly advance the research of biological mechanisms and treatment of cancer. This review summarizes the mechanism and development of CRISPR/Cas9 gene-editing technology in recent years and descri...
Source: Clinical Genetics - September 14, 2023 Category: Genetics & Stem Cells Authors: Li Ning Jiahui Xi Yin Zi Min Chen Qingjian Zou Xiaoqing Zhou Chengcheng Tang Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Evaluation of the quality of guidelines for sublingual immunotherapy of allergic rhinitis
ConclusionThe quality of the current guidelines for sublingual immunotherapy is average. The formulation methodology and reporting standards of these guidelines must be developed. By standardizing the treatment of sublingual immunotherapy properly, it is recommended that guideline makers refer to the AGREE II to formulate high-quality guidelines and promote their wide application.
Source: European Archives of Oto-Rhino-Laryngology - September 13, 2023 Category: ENT & OMF Source Type: research
Prolonged haematologic toxicity in CAR-T-cell therapy: A review
J Cell Mol Med. 2023 Sep 13. doi: 10.1111/jcmm.17930. Online ahead of print.ABSTRACTChimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its r...
Source: J Cell Mol Med - September 13, 2023 Category: Molecular Biology Authors: Qi Liu Tonglin Hu Hangchao Li Yingying Shen Dijiong Wu Baodong Ye Source Type: research
